Equities

Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ)

Actions
  • Price (EUR)0.388
  • Today's Change-0.02 / -4.90%
  • Shares traded0.00
  • 1 Year change+9.60%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments303128144
Total Receivables, Net36106.80
Total Inventory0.700.600.69
Prepaid expenses5.508.901.45
Other current assets, total----0.00
Total current assets346147153
Property, plant & equipment, net4.402.704.28
Goodwill, net------
Intangibles, net409410411
Long term investments0.800.800.79
Note receivable - long term------
Other long term assets----0
Total assets760561569
LIABILITIES
Accounts payable29204.60
Accrued expenses632417
Notes payable/short-term debt000
Current portion long-term debt/capital leases7.401.601.50
Other current liabilities, total4.804.1016
Total current liabilities1044939
Total long term debt1061.102.65
Total debt1132.704.15
Deferred income tax------
Minority interest------
Other liabilities, total5.104.400.41
Total liabilities2155542
SHAREHOLDERS EQUITY
Common stock15118.69
Additional paid-in capital1,7801,4281,263
Retained earnings (accumulated deficit)(1250)(934)(744)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total----0.00
Total equity546506527
Total liabilities & shareholders' equity760561569
Total common shares outstanding293215180
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.